Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dietlein

Showing results (21-30 of 140) with videos related to

Pageof 14
Sort By:
Nuclear Medicine Communications|December 18, 2004
Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?Markus Dietlein, Walter A Luyken, Harald Schicha, et al.
The American Journal of Medicine|May 30, 2002
Differentiation between healthy thyroid remnants and tumor tissue after radioiodine therapy in patients with differentiated thyroid carcinoma using in vitro phosphorus-31 magnetic resonance spectroscopyDetlef Moka, Markus Dietlein, Klaus Raffelt, et al.
Nuklearmedizin. Nuclear Medicine|April 7, 2022
Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral centerPeter J Müller, Markus Dietlein, Carsten Kobe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2008
Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinomaFrederik A Verburg, Markus Dietlein, Michael Lassmann, et al.
Leukemia & Lymphoma|April 15, 2003
Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphomaMartin R Weihrauch, Markus Dietlein, Harald Schicha, et al.
Nuklearmedizin. Nuclear Medicine|June 29, 2016
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4]Markus Dietlein, Wolfgang Eschner, Frank Grünwald, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 14, 2010
EANM procedure guidelines for therapy of benign thyroid diseaseMarcel P M Stokkel, Daria Handkiewicz Junak, Michael Lassmann, et al.
Nuklearmedizin. Nuclear Medicine|December 7, 2016
[Radioiodine therapy for benign thyroid diseases (version 5). German Guideline]Markus Dietlein, Frank Grünwald, Matthias Schmidt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 19, 2011
One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancerMarkus Dietlein, F A Verburg, M Luster, et al.
Nuklearmedizin. Nuclear Medicine|August 21, 2018
[Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma]Frederik A Verburg, Frank Grünwald, Michael Lassmann, et al.
Pageof 14

Showing results (21-30 of 140) with videos related to

Sort By:
Pageof 14
Nuclear Medicine Communications|December 18, 2004
Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?Markus Dietlein, Walter A Luyken, Harald Schicha, et al.
The American Journal of Medicine|May 30, 2002
Differentiation between healthy thyroid remnants and tumor tissue after radioiodine therapy in patients with differentiated thyroid carcinoma using in vitro phosphorus-31 magnetic resonance spectroscopyDetlef Moka, Markus Dietlein, Klaus Raffelt, et al.
Nuklearmedizin. Nuclear Medicine|April 7, 2022
Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral centerPeter J Müller, Markus Dietlein, Carsten Kobe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2008
Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinomaFrederik A Verburg, Markus Dietlein, Michael Lassmann, et al.
Leukemia & Lymphoma|April 15, 2003
Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphomaMartin R Weihrauch, Markus Dietlein, Harald Schicha, et al.
Nuklearmedizin. Nuclear Medicine|June 29, 2016
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4]Markus Dietlein, Wolfgang Eschner, Frank Grünwald, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 14, 2010
EANM procedure guidelines for therapy of benign thyroid diseaseMarcel P M Stokkel, Daria Handkiewicz Junak, Michael Lassmann, et al.
Nuklearmedizin. Nuclear Medicine|December 7, 2016
[Radioiodine therapy for benign thyroid diseases (version 5). German Guideline]Markus Dietlein, Frank Grünwald, Matthias Schmidt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 19, 2011
One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancerMarkus Dietlein, F A Verburg, M Luster, et al.
Nuklearmedizin. Nuclear Medicine|August 21, 2018
[Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma]Frederik A Verburg, Frank Grünwald, Michael Lassmann, et al.
Pageof 14